Related Experiment Video
Updated: Aug 9, 2026
09:00
Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Gene therapy for adenosine deaminase deficiency
Alessandro Aiuti1, Francesca Ficara, Federica Cattaneo
1San Raffaele-Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy. a.aiuti@hsr.it
Current Opinion in Allergy and Clinical Immunology
|November 13, 2003
Summary
Gene therapy for adenosine deaminase deficiency has shown promising results. Improved gene transfer in stem cells offers clinical benefit and restores immune function without adverse effects.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency is a rare genetic disorder.
- Gene therapy aims to correct the underlying genetic defect in ADA-SCID.
Purpose of the Study:
- To review the latest advances in gene therapy trials for ADA-SCID.
- To evaluate gene therapy using peripheral blood lymphocytes and hematopoietic progenitors.
Main Methods:
- Gene transfer into peripheral blood lymphocytes.
- Gene transfer into hematopoietic progenitors (CD34+ cells).
- Combination with nonmyeloablative conditioning.
Main Results:
- Long-term persistence of gene-corrected T cells observed.
- Improved gene transfer protocols in CD34+ cells led to stable engraftment and multilineage reconstitution.
- Restoration of immune functions and metabolic defect correction achieved.
- Clinical benefit demonstrated without adverse effects.
Conclusions:
- Gene transfer into hematopoietic stem cells with nonmyeloablative conditioning is effective for ADA-SCID.
- This approach holds potential for treating other hematopoietic disorders.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
02:23RNA Editing
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...